WAVE LIFE SCIENCES LTD. Excess Tax Benefit from Share-based Compensation, Operating Activities
WAVE LIFE SCIENCES LTD. (WVE) reported Excess Tax Benefit from Share-based Compensation, Operating Activities of $310.00 thousand for the 12-month period ending 2016-12-31, per its 10-K filed 2019-03-01.
Discontinued › Notes › Compensation Related Costs
us-gaap:ExcessTaxBenefitFromShareBasedCompensationOperatingActivities · last filed 2019-03-01
- WAVE LIFE SCIENCES LTD. excess tax benefit from share-based compensation, operating activities for the quarter ending 2016-12-31 was $243.00K.
- WAVE LIFE SCIENCES LTD. excess tax benefit from share-based compensation, operating activities for fiscal 2016 was $310.00K.
| Period end | Excess Tax Benefit from Share-based Compensation, Operating Activities 3 month | Excess Tax Benefit from Share-based Compensation, Operating Activities 9 month | Excess Tax Benefit from Share-based Compensation, Operating Activities 12 month |
|---|---|---|---|
| 2016-12-31 | $243.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | $310.00K 10-K · filed 2019-03-01 | |
| 2016-09-30 | $67.00K 10-Q · filed 2017-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |